ONESOURCE SPECL PHARMA L (ONESOURCE) financials

ONESOURCE SPECL PHARMA L (ONESOURCE) NSE/BSE financials on Fincrux: quarterly results, profit and loss, cash flow, balance sheet, ratios, and shareholding.

Incorporated in 2007, OneSource Specialty Pharma Ltd is in the research, development, manufacture and commercialisation of biological drug products in various injectable formats. It also offers end-to-end CDMOservices across all phases of pre-clinicaland clinical development and commercialsupply of biologics[1]

Market Cap: ₹15,562Cr.
Current Price: ₹1,357
Stock P/E: 293
ROE: 0.45%
ROCE: 2.05%
Book Value: ₹519
Dividend Yield: 0.00%
52W High / Low: ₹1,925/1,057

In Jun 2026, ONESOURCE SPECL PHARMA L (ONESOURCE) reported sales ₹446 Cr and net profit ₹51 Cr.

Annual TTM: sales ₹1,531 Cr, net profit ₹48 Cr.

Shareholding: Promoters 30.47% (Sep 2026), FIIs 19.45% (Sep 2026), DIIs 24.20% (Sep 2026), Public 25.86% (Sep 2026), No. of Shareholders 79,770% (Sep 2026).

ONESOURCE quarterly results (₹ Cr.)
Category	Sep 2024	Dec 2024	Mar 2025	Jun 2025	Sep 2025	Dec 2025	Mar 2026	Jun 2026
Sales	245	337	477	321	375	290	419	446
Expenses	223	237	240	241	274	277	344	332
Operating Profit	22	99	237	80	102	13	75	114
OPM %	9%	30%	50%	25%	27%	4.4%	18%	26%
Other Income	-3	-95	3	5	3	-2	4	4
Interest	44	44	32	27	33	38	22	31
Depreciation	33	34	34	33	34	35	35	36
Profit before tax	-58	-73	174	25	37	-62	21	51
Tax %	0%	0%	0%	0%	0%	0%	0%	0%
Net Profit	-58	-73	174	25	37	-62	21	51
EPS in Rs	—	-6.38	15.22	2.17	3.24	-5.43	1.87	4.47
Raw PDF	—	—	—	—	—	—	—	—

ONESOURCE profit and loss (₹ Cr.)
Category	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026	TTM
Sales	21	132	39	172	1,300	1,405	1,531
Expenses	93	228	156	254	930	1,136	1,228
Operating Profit	-72	-96	-117	-82	370	269	303
OPM %	-337%	-72%	-303%	-48%	28%	19%	20%
Other Income	1	4	-525	-143	-95	9	8
Interest	16	68	48	89	162	121	124
Depreciation	34	70	109	76	135	137	140
Profit before tax	-121	-230	-799	-390	-22	21	48
Tax %	0%	0%	0%	0%	-187%	0%	—
Net Profit	-121	-230	-799	-390	19	21	48
EPS in Rs	—	—	—	—	1.69	1.85	4.15
Dividend Payout %	0%	0%	0%	0%	0%	0%	—

ONESOURCE balance sheet (₹ Cr.)
Category	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026
Equity Capital	2	4	4	4	11	11
Reserves	777	1,012	783	394	5,909	5,939
Borrowings	386	1,154	864	571	942	1,504
Other Liabilities	98	275	363	457	635	916
Total Liabilities	1,262	2,445	2,014	1,426	7,497	8,370
Fixed Assets	633	1,231	1,361	863	3,200	3,198
CWIP	382	440	334	188	206	469
Investments	53	52	5	20	2,848	2,931
Other Assets	194	722	314	355	1,243	1,773
Total Assets	1,262	2,445	2,014	1,426	7,497	8,370

ONESOURCE cash flows (₹ Cr.)
Category	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026
Cash from Operating Activity	-115	-420	-165	-109	-47	55
Cash from Investing Activity	-210	-685	-66	506	-300	-478
Cash from Financing Activity	381	1,159	118	-384	417	361
Net Cash Flow	56	55	-112	13	70	-61
Free Cash Flow	-274	-1,069	-207	-173	-134	-421
CFO/EBITDA Share of operating profit converting into cash: CFO (before tax) / Operating Profit	159%	439%	150%	133%	-11%	19%

ONESOURCE shareholding pattern (%)
Category	Dec 2024	Mar 2025	Jun 2025	Sep 2025	Dec 2025	Mar 2026	Jun 2026	Sep 2026
Promoters	37.76%	34.25%	29.78%	29.77%	29.93%	30.48%	30.48%	30.47%
FIIs	17.44%	18.54%	18.69%	19.39%	19.24%	17.50%	19.19%	19.45%
DIIs	12.56%	18.03%	18.09%	18.48%	18.80%	20.61%	23.37%	24.20%
Public	32.24%	29.17%	33.42%	32.34%	32.01%	31.40%	26.95%	25.86%
No. of Shareholders	98,425	82,712	87,760	87,416	84,595	79,460	77,899	79,770

ONESOURCE key ratios
Category	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026
Debtor Days	38	101	35	118	124	191
Inventory Days	87	1,720	2,354	665	233	438
Days Payable	758	408	1,606	419	143	330
Cash Conversion Cycle	-633	1,414	784	363	214	299
Working Capital Days	-2,423	-1,288	-6,731	-873	-49	-18
ROCE %	—	-10%	-12%	-12%	6%	2%

ONESOURCEUpdated 22 Oct 2026, 5:53

Onesource Specl Pharma L

ONESOURCEUpdated 22 Oct 2026, 5:53

Market Cap

₹15,562Cr.

Current Price

₹1,357

High / Low

₹1,925/1,057

Stock P/E

293

ROE0.45%

ROCE2.05%

Book Value₹519

Face Value₹1.00

Dividend Yield0.00%

About

Quarterly results

Last reported quarters₹ Cr.

Quarter	Sales	Interest	Expenses	Other Income	Depreciation	Profit Before Tax	Tax	Net Profit	EPS (₹)
Sep 2023	34	25	72	-32	18	-113	0	-113	—
Dec 2023	56	26	67	-74	20	-130	0	-130	—
Mar 2024	73	20	76	3	20	-40	0	-40	—
Jun 2024	240	41	230	-1	34	-65	-63	-24	—
Sep 2024	245	44	223	-3	33	-58	0	-58	—
Dec 2024	337	44	237	-95	34	-73	0	-73	-6.38
Mar 2025	477	32	240	3	34	174	0	174	15.22
Jun 2025	321	27	241	5	33	25	0	25	2.17
Sep 2025	375	33	274	3	34	37	0	37	3.24
Dec 2025	290	38	277	-2	35	-62	0	-62	-5.43
Mar 2026	419	22	344	4	35	21	0	21	1.87
Jun 2026	446	31	332	4	36	51	0	51	4.47

Profit & loss

Annual statement₹ Cr.

Year	Sales	Interest	Expenses	Other Income	Depreciation	Profit Before Tax	Tax	Net Profit	EPS (₹)
Mar 2021	21	16	93	1	34	-121	0	-121	—
Mar 2022	132	68	228	4	70	-230	0	-230	—
Mar 2023	39	48	156	-525	109	-799	0	-799	—
Mar 2024	172	89	254	-143	76	-390	0	-390	—
Mar 2025	1300	162	930	-95	135	-22	-187	19	1.69
Mar 2026	1405	121	1136	9	137	21	0	21	1.85
TTM	1531	124	1228	8	140	48	—	48	4.15

Shareholding pattern

As of Sep 2026%

Holder	Share
Promoters	30.47%
FIIs	19.45%
DIIs	24.2%
Public	25.86%

Shareholding trend

Ownership over time%

Quarter	Promoters	FIIs	DIIs	Public
Dec 2024	37.76%	17.44%	12.56%	32.24%
Mar 2025	34.25%	18.54%	18.03%	29.17%
Jun 2025	29.78%	18.69%	18.09%	33.42%
Sep 2025	29.77%	19.39%	18.48%	32.34%
Dec 2025	29.93%	19.24%	18.8%	32.01%
Mar 2026	30.48%	17.5%	20.61%	31.4%
Jun 2026	30.48%	19.19%	23.37%	26.95%
Sep 2026	30.47%	19.45%	24.2%	25.86%

Balance sheet

Assets & liabilities₹ Cr.

Period	Equity Capital	Reserves	Borrowings	Other Liabilities	Total Liabilities	Fixed Assets	CWIP	Investments	Other Assets	Total Assets
Mar 2021	2	777	386	98	1262	633	382	53	194	1262
Mar 2022	4	1012	1154	275	2445	1231	440	52	722	2445
Mar 2023	4	783	864	363	2014	1361	334	5	314	2014
Mar 2024	4	394	571	457	1426	863	188	20	355	1426
Mar 2025	11	5909	942	635	7497	3200	206	2848	1243	7497
Mar 2026	11	5939	1504	916	8370	3198	469	2931	1773	8370

Cash flows

Operating, investing & financing₹ Cr.

Period	Operating	Investing	Financing	Net cash flow
Mar 2021	-115	-210	381	56
Mar 2022	-420	-685	1159	55
Mar 2023	-165	-66	118	-112
Mar 2024	-109	506	-384	13
Mar 2025	-47	-300	417	70
Mar 2026	55	-478	361	-61

Key ratios

Historical financial ratios

Category	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026
Debtor Days	38	101	35	118	124	191
Inventory Days	87	1,720	2,354	665	233	438
Days Payable	758	408	1,606	419	143	330
Cash Conversion Cycle	-633	1,414	784	363	214	299
Working Capital Days	-2,423	-1,288	-6,731	-873	-49	-18
ROCE %	—	-10%	-12%	-12%	6%	2%

Frequently asked questions

Quick answers about this company's financials on Fincrux

What is the market cap of ONESOURCE SPECL PHARMA L (ONESOURCE)?

The reported market capitalisation for ONESOURCE SPECL PHARMA L (ONESOURCE) is ₹15,562Cr. on Fincrux. Figures may update with market data and filings.

What is the current share price of ONESOURCE?

The current price shown for ONESOURCE SPECL PHARMA L (ONESOURCE) on Fincrux is ₹1,357 with a 52-week high/low of ₹1,925/1,057.

What is the P/E ratio of ONESOURCE SPECL PHARMA L (ONESOURCE)?

The stock P/E for ONESOURCE SPECL PHARMA L (ONESOURCE) is 293 on Fincrux, with ROE at 0.45% and ROCE at 2.05%.

What were ONESOURCE latest quarterly results?

For Jun 2026, ONESOURCE SPECL PHARMA L (ONESOURCE) reported sales ₹446 Cr and net profit ₹51 Cr (figures in ₹ crore unless noted).

What are ONESOURCE annual sales and net profit?

For TTM, ONESOURCE SPECL PHARMA L (ONESOURCE) shows sales of ₹1,531 Cr and net profit of ₹48 Cr on the Fincrux profit & loss statement.

Who owns ONESOURCE SPECL PHARMA L (ONESOURCE)?

Latest shareholding for ONESOURCE SPECL PHARMA L (ONESOURCE) on Fincrux: Promoters 30.47% (Sep 2026), FIIs 19.45% (Sep 2026), DIIs 24.20% (Sep 2026), Public 25.86% (Sep 2026), No. of Shareholders 79,770% (Sep 2026).

Where can I find ONESOURCE SPECL PHARMA L (ONESOURCE) financials?

ONESOURCE SPECL PHARMA L (ONESOURCE) financials on Fincrux include quarterly results, profit and loss, cash flow, balance sheet, key ratios, and shareholding patterns for NSE/BSE research.

Does Fincrux show ONESOURCE balance sheet and cash flow?

Yes. The ONESOURCE SPECL PHARMA L (ONESOURCE) page on Fincrux includes balance sheet, cash flow statements, historical ratios, and ownership trends alongside quarterly and annual results.

Figures in ₹ crore unless noted. Data sourced for research and may lag filings.

Last updated 22 October 2026 at 5:53